• Something wrong with this record ?

Thyroid Cancer Detection in a Routine Clinical Setting: Performance of ACR TI-RADS, FNAC, and Molecular Testing in Prospective Cohort Study

T. Grimmichova, P. Pacesova, M. Hill, B. Pekova, M. Vankova, J. Moravcova, J. Vrbikova, Z. Novak, K. Mastnikova, E. Vaclavikova, J. Vcelak, B. Bendlova, J. Drozenova, V. Sykorova

. 2022 ; 10 (5) : . [pub] 20220420

Language English Country Switzerland

Document type Journal Article

Grant support
AZV (NU21-01-00448) Government of the Czech Republic
EU 00023761 Government of the Czech Republic

The aim of our study was to address the potential for improvements in thyroid cancer detection in routine clinical settings using a clinical examination, the American College of Radiology Thyroid Imaging Reporting and Database System (ACR TI-RADS), and fine-needle aspiration cytology (FNAC) concurrently with molecular diagnostics. A prospective cohort study was performed on 178 patients. DNA from FNA samples was used for next-generation sequencing to identify mutations in the genes BRAF, HRAS, KRAS, NRAS, and TERT. RNA was used for real-time PCR to detect fusion genes. The strongest relevant positive predictors for malignancy were the presence of genetic mutations (p < 0.01), followed by FNAC (p < 0.01) and ACR TI-RADS (p < 0.01). Overall, FNAC, ACR TI-RADS, and genetic testing reached a sensitivity of up to 96.1% and a specificity of 88.3%, with a diagnostic odds ratio (DOR) of 183.6. Sensitivity, specificity, and DOR decreased to 75.0%, 88.9%, and 24.0, respectively, for indeterminate (Bethesda III, IV) FNAC results. FNA molecular testing has substantial potential for thyroid malignancy detection and could lead to improvements in our approaches to patients. However, clinical examination, ACR TI-RADS, and FNAC remained relevant factors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017345
003      
CZ-PrNML
005      
20241111144447.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines10050954 $2 doi
035    __
$a (PubMed)35625691
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Grimmichova, Tereza $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $u Internal Clinic, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Srobarova 1150/50, 10034 Prague, Czech Republic $1 https://orcid.org/000000022355540X
245    10
$a Thyroid Cancer Detection in a Routine Clinical Setting: Performance of ACR TI-RADS, FNAC, and Molecular Testing in Prospective Cohort Study / $c T. Grimmichova, P. Pacesova, M. Hill, B. Pekova, M. Vankova, J. Moravcova, J. Vrbikova, Z. Novak, K. Mastnikova, E. Vaclavikova, J. Vcelak, B. Bendlova, J. Drozenova, V. Sykorova
520    9_
$a The aim of our study was to address the potential for improvements in thyroid cancer detection in routine clinical settings using a clinical examination, the American College of Radiology Thyroid Imaging Reporting and Database System (ACR TI-RADS), and fine-needle aspiration cytology (FNAC) concurrently with molecular diagnostics. A prospective cohort study was performed on 178 patients. DNA from FNA samples was used for next-generation sequencing to identify mutations in the genes BRAF, HRAS, KRAS, NRAS, and TERT. RNA was used for real-time PCR to detect fusion genes. The strongest relevant positive predictors for malignancy were the presence of genetic mutations (p &lt; 0.01), followed by FNAC (p &lt; 0.01) and ACR TI-RADS (p &lt; 0.01). Overall, FNAC, ACR TI-RADS, and genetic testing reached a sensitivity of up to 96.1% and a specificity of 88.3%, with a diagnostic odds ratio (DOR) of 183.6. Sensitivity, specificity, and DOR decreased to 75.0%, 88.9%, and 24.0, respectively, for indeterminate (Bethesda III, IV) FNAC results. FNA molecular testing has substantial potential for thyroid malignancy detection and could lead to improvements in our approaches to patients. However, clinical examination, ACR TI-RADS, and FNAC remained relevant factors.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pacesova, Petra $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
700    1_
$a Hill, Martin $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/0000000217050835 $7 mzk2005304431
700    1_
$a Peková Bulanová, Barbora, $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/000000028571164X $d 1993- $7 xx0256338
700    1_
$a Vankova, Marketa $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/0000000318837274
700    1_
$a Moravcova, Jitka $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/0000000317050744
700    1_
$a Vrbikova, Jana $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
700    1_
$a Novak, Zdenek $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
700    1_
$a Mastnikova, Karolina $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
700    1_
$a Vaclavikova, Eliska $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
700    1_
$a Vcelak, Josef $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
700    1_
$a Bendlova, Bela $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
700    1_
$a Drozenova, Jana $u Department of Pathology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Srobarova 1150/50, 10034 Prague, Czech Republic
700    1_
$a Sykorova, Vlasta $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/0000000234491472
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 10, č. 5 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35625691 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20241111144444 $b ABA008
999    __
$a ind $b bmc $g 1816548 $s 1168587
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 10 $c 5 $e 20220420 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
GRA    __
$a AZV (NU21-01-00448) $p Government of the Czech Republic
GRA    __
$a EU 00023761 $p Government of the Czech Republic
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...